Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment

Horm Metab Res. 2014 Feb;46(2):145-9. doi: 10.1055/s-0033-1351250. Epub 2013 Aug 5.

Abstract

Periostin is a secreted extracellular matrix protein preferentially expressed in bone by osteocytes and periosteal osteoblasts. Reduced periostin expression may affect osteoblast differentiation and collagen type I synthesis and predispose to osteoporosis and increased fracture risk. We aimed to evaluate circulating periostin levels in postmenopausal women with low bone mass, their possible correlations with clinical and laboratory parameters, as well as the 3-month effect of zoledronic acid. Serum samples for periostin, 25-hydroxyvitamin D, parathyroid hormone (PTH), C-terminal telopeptide of type I collagen (CTx), and total alkaline phosphatase (tALP) were obtained from 46 postmenopausal women with low bone mass at baseline and 3 months after zoledronic acid infusion and from 30 age-matched, postmenopausal controls with normal bone mass at baseline. There was no difference in periostin levels between women with normal and low bone mass (250±15 vs. 272±14 ng/ml, respectively; p=0.279). Periostin remained essentially unchanged after zoledronic acid infusion (262±18 ng/ml; p=0.130). Serum periostin levels at baseline were not affected by previous bisphosphonate treatment, and were correlated only to tALP (rs=0.351; p=0.018). In multiple linear regression analysis, tALP (B=3.17; 95% CI=0.59-5.79; p=0.018) was associated with serum periostin levels at baseline, independently from previous anti-osteoporotic treatment, age, body mass index, and 25-hydroxyvitamin D. In conclusion, serum periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment. Women with higher tALP have independently higher periostin levels.

MeSH terms

  • Aged
  • Alkaline Phosphatase / blood
  • Bone Density Conservation Agents / administration & dosage*
  • Bone Density*
  • Cell Adhesion Molecules / blood*
  • Collagen Type I / blood
  • Diphosphonates / administration & dosage*
  • Female
  • Humans
  • Imidazoles / administration & dosage*
  • Middle Aged
  • Parathyroid Hormone / blood
  • Peptides / blood
  • Postmenopause / blood*
  • Vitamin D / analogs & derivatives
  • Vitamin D / blood
  • Zoledronic Acid

Substances

  • Bone Density Conservation Agents
  • Cell Adhesion Molecules
  • Collagen Type I
  • Diphosphonates
  • Imidazoles
  • POSTN protein, human
  • Parathyroid Hormone
  • Peptides
  • collagen type I trimeric cross-linked peptide
  • Vitamin D
  • Zoledronic Acid
  • 25-hydroxyvitamin D
  • Alkaline Phosphatase